Use of Catestatin to Mobilize Fat from Adipose Tissue by Regulating Adrenergic and Leptin Signaling

Tech ID: 22551 / UC Case 2012-314-0


Chromogranin A (CHGA/Chga), a 48-kDa acidic secretory proprotein, gives rise to several peptides of biological importance, which include the dysglycemic hormone pancreastatin, the vasodilator vasostatin, and the antihypertensive peptide catestatin that inhibits catecholamine release. Initially identified as a physiological brake in catecholamine secretion, catestatin has been established as a pleiotropic hormone having effects on promoting angiogenesis and lowering blood pressure.

Technology Description

Scientists at the University of California, San Diego have discovered that catestatin reduces adipose tissue weight by stimulating breakdown of fat (lipolysis) and disposing of the released fatty acids by oxidation in both liver and adipose tissue. This technology supports an essential role of the endogenous bioactive peptide catestatin in restoring homeostasis during metabolic disorders by controlling catecholamine release and lipid disposal via modulation of adrenergic and leptin signaling. Therefore, CST may be developed as an anti-obesity agent.

Related Materials

Patent Status

Country Type Number Dated Case
United States Of America Issued Patent 9,572,862 02/21/2017 2012-314


Learn About UC TechAlerts - Save Searches and receive new technology matches


  • Mahata, Sushil K.

Other Information


catestatin, triglyceride, glycerol, fatty acid

Categorized As